Omnicell, Inc. (OMCL)
| Market Cap | 1.71B +20.6% |
| Revenue (ttm) | 1.25B +8.5% |
| Net Income | 39.08M +69.3% |
| EPS | 0.84 +70.7% |
| Shares Out | 45.61M |
| PE Ratio | 44.53 |
| Forward PE | 20.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,740 |
| Open | 37.41 |
| Previous Close | 37.13 |
| Day's Range | 37.28 - 37.96 |
| 52-Week Range | 29.06 - 55.00 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 57.86 (+54.58%) |
| Earnings Date | Jul 30, 2026 |
About OMCL
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-hous... [Read more]
Financial Performance
In 2025, Omnicell's revenue was $1.18 billion, an increase of 6.53% compared to the previous year's $1.11 billion. Earnings were $2.05 million, a decrease of -83.62%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for OMCL stock is "Strong Buy." The 12-month stock price target is $57.86, which is an increase of 54.58% from the latest price.
News
Omnicell management to meet virtually with Freedom Capital
Virtual Meeting to be held on August 13 hosted by Freedom Capital.
Omnicell price target lowered to $45 from $55 at Piper Sandler
Piper Sandler lowered the firm’s price target on Omnicell (OMCL) to $45 from $55 and keeps an Overweight rating on the shares. The firm notes the company reported strong Q2…
Omnicell price target lowered to $65 from $70 at KeyBanc
KeyBanc lowered the firm’s price target on Omnicell (OMCL) to $65 from $70 and keeps an Overweight rating on the shares. The firm notes Q2 saw solid results, but Omnicell…
Omnicell price target lowered to $50 from $55 at Wells Fargo
Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on Omnicell (OMCL) to $50 from $55 and keeps an Overweight rating on the shares. The firm says the stock…
EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination
FORT WORTH, Texas--(BUSINESS WIRE)--EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination.
Omnicell Earnings Call Transcript: Q2 2026
Q2 2026 results exceeded expectations with strong revenue, profitability, and cash flow, driven by robust demand for Titan XT and OmniSphere. Guidance for bookings was widened due to timing uncertainty, but customer engagement and pipeline remain strong.
Omnicell Earnings release: Q2 2026
Omnicell released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Omnicell Slides: Q2 2026
Omnicell has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Omnicell Quarterly report: Q2 2026
Omnicell has published its Q2 2026 quarterly earnings report on July 30, 2026.
Omnicell reports Q2 non-GAAP EPS 94c, consensus 47c
Reports Q2 revenue $312M, consensus $310.22M. “We delivered solid second quarter results and continued to execute against our strategic priorities,” said CEO Randall Lipps. “We believe our performance...
Omnicell sees Q3 non-GAAP EPS 35c-43c, consensus 47c
Sees Q3 revenue $301M-$307M, consensus $312.53M.
Omnicell sees 2026 non-GAAP EPS $2.15-$2.30, consensus $1.94
Sees 2026 revenue $1.23B-$1.25B, consensus $1.25B.
Omnicell Announces Second Quarter 2026 Financial Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Second Quarter 2026 Financial Results.
Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026.
Omnicell appoints Njoku as President of the Company
Omnicell (OMCL) announced that Nnamdi Njoku has been appointed President of the Company, effective July 1, 2026. Njoku will retain his role of Chief Operating Officer, COO, while Randall Lipps…
Nnamdi Njoku Appointed President of Omnicell
FORT WORTH, Texas--(BUSINESS WIRE)--Nnamdi Njoku appointed President of Omnicell leading global operations & innovation strategy; Randall Lipps continues as CEO, Chairman of the Board.
Omnicell Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Growth has resumed after a challenging period, driven by new product launches, a shift to software and cloud-based services, and expansion into specialty pharmacy. The company is managing a major product transition, focusing on AI-driven solutions, and expects improved margins and strong market opportunities in the coming years.
Omnicell appoints Dan Mandoli as GM, Specialty Pharmacy Services
Omnicell (OMCL) announced that Dan Mandoli has joined the Company as Senior Vice President and General Manager, Specialty Pharmacy Services. Most recently, Mr. Mandoli served as COO at Altruix. Publis...
Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business
FORTH WORTH, Texas--(BUSINESS WIRE)--Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business.
Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026.
Omnicell management to meet with Craig-Hallum
Meeting to be held in Minneapolis on June 1 hosted by Craig-Hallum.
Omnicell announces removal of i.vSTATION syringe labels
The FDA is aware that Omnicell (OMCL) has issued a letter to affected customers recommending certain syringe labels used with the i.v.STATION automated compounding system be removed from where they…
Omnicell Transcript: Bank of America Global Healthcare Conference 2026
The conference highlighted a strategic focus on launching Titan XT and OmniSphere, driving a major product transition and targeting margin expansion through disciplined execution and investment. Management expects a multi-year capital cycle, stable hospital CapEx, and renewed optimism in retail pharmacy.
Omnicell to Present at the BofA Securities 2026 Healthcare Conference
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the BofA Securities 2026 Healthcare Conference.
Omnicell price target raised to $55 from $53 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Omnicell (OMCL) to $55 from $53 and keeps a Buy rating on the shares. Following the company’s beat and raise quarter, the firm…